Clinical Study

An Open-Label, Multicenter Phase 4 Study To Assess Disease Activity And Biomarkers Of Neuronal Damage In Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

Posted Date: Mar 19, 2021

  • Investigator: Lawrence Goldstick
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

The primary objective of this study is to assess disease activity during treatment with ocrelizumab in minorities represented by Black/African Americans with RMS and Hispanic/Latinos with RMS.


Participant Must Be Between 18-65 And Have Been Diagnosed With Relapsing Multiple Sclerosis (Rms). Participant Must Identify As Black/African- American Or Hispanic/Latino. Patient Must Have Been On A Maximum Of 2 Prior Ms Medications.


Relapsing Multiple Sclerosis, Neurology, Ocrelizumab

For More Information:


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.